IL17A and Crohn disease: Antibody blockade of IFN-γ is largely disappointing in Crohn’s disease (Reinisch et al., 2010), and preliminary data appear to show that anti-IL-17A therapy lacks efficacy or even exacerbates Crohn’s disease (W. Hueber et al., 2011, J. Crohns Colitis, abstract).